Literature DB >> 16537689

Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy.

Shunichi Namiki1, Shigeto Ishidoya, Tatsuo Tochigi, Sadafumi Kawamura, Masaaki Kuwahara, Akito Terai, Koji Yoshimura, Isao Numata, Makoto Satoh, Seiichi Saito, Yoshihiro Takai, Shogo Yamada, Yoichi Arai.   

Abstract

OBJECTIVE: No previous studies have reported the longitudinal health-related quality of life (HRQOL) for intensity modulated radiation therapy (IMRT). We compared HRQOL after IMRT with that after conventional and after conformal radiation therapy (XRT).
METHODS: A total of 110 patients underwent XRT (34 patients underwent conventional radiation therapy and 76 underwent conformal radiation therapy) and 30 underwent IMRT for clinically localized prostate cancer between 2000 and 2002. We measured the general and disease-specific HRQOL using the Medical Outcomes Study 36-Item Health Survey and University of California, Los Angeles, Prostate Cancer Index, respectively.
RESULTS: There were no significant differences in the preoperative characteristics and HRQOL scores of the two groups. Repeated measure analyses of variance revealed significantly different patterns of alteration in several general HRQOL domains between XRT and the IMRT groups. In the urinary domain, there was no difference in the alteration patterns between the two groups. The XRT group suffered worse bowel function at 3 and 6 months than the IMRT group (P < 0.05). In the XRT group, sexual function decreased at 3 months and remained substantially lower than the baseline level. However, the IMRT group showed no significant difference from the baseline level at any of the observation periods. At 18 months the XRT group showed worse sexual function than the IMRT group.
CONCLUSION: The two approaches showed different longitudinal profiles regarding general and disease-specific HRQOL during the first 2 years after treatment. The IMRT approach produced little impairment in bowel and sexual function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537689     DOI: 10.1093/jjco/hyl002

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  11 in total

1.  Cakes for cure: the role of charities in the embedding of innovative cancer treatment technologies.

Authors:  Lisa Ashmore
Journal:  Health Expect       Date:  2011-05-25       Impact factor: 3.377

2.  Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial.

Authors:  Deborah W Bruner; Daniel Hunt; Jeff M Michalski; Walter R Bosch; James M Galvin; Mahul Amin; Canhua Xiao; Jean-Paul Bahary; Malti Patel; Susan Chafe; George Rodrigues; Harold Lau; Marie Duclos; Madhava Baikadi; Snehal Deshmukh; Howard M Sandler
Journal:  Cancer       Date:  2015-04-02       Impact factor: 6.860

3.  Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  Kathryn L Taylor; George Luta; Anthony B Miller; Timothy R Church; Scott P Kelly; Larry R Muenz; Kimberly M Davis; David L Dawson; Sara Edmond; Douglas Reding; Jerome E Mabie; Thomas L Riley
Journal:  J Clin Oncol       Date:  2012-06-25       Impact factor: 44.544

4.  Radical radiotherapy for high-risk prostate cancer in older men.

Authors:  Heather A Payne; Simon Hughes
Journal:  Oncologist       Date:  2012

5.  Comparison of prostate IMRT and VMAT biologically optimised treatment plans.

Authors:  Nicholas Hardcastle; Wolfgang A Tomé; Kerwyn Foo; Andrew Miller; Martin Carolan; Peter Metcalfe
Journal:  Med Dosim       Date:  2010-08-30       Impact factor: 1.482

6.  Quality-of-life outcomes in high-risk prostate cancer patients treated with helical tomotherapy in a hypofractionated radiation schedule with long-term androgen suppression.

Authors:  N Pervez; A V Krauze; D Yee; M Parliament; A Mihai; S Ghosh; K Joseph; A Murtha; J Amanie; M Kamal; R Pearcey
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

Review 7.  Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment.

Authors:  Cem Akbal; Ilker Tinay; Ferruh Simşek; Levent N Turkeri
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

8.  Quality of life among elderly men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.

Authors:  Shunichi Namiki; Shigeto Ishidoya; Sadafumu Kawamura; Tatsuo Tochigi; Yoichi Arai
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-02       Impact factor: 4.553

9.  Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer.

Authors:  Aurore Goineau; Virginie Marchand; Jérome Rigaud; Sylvain Bourdin; Emmanuel Rio; Loic Campion; Angélique Bonnaud-Antignac; Marc-André Mahé; Stéphane Supiot
Journal:  Radiat Oncol       Date:  2013-03-06       Impact factor: 3.481

Review 10.  Quality of Life and Sexual Health in the Aging of PCa Survivors.

Authors:  Mauro Gacci; Elisabetta Baldi; Lara Tamburrino; Beatrice Detti; Lorenzo Livi; Cosimo De Nunzio; Andrea Tubaro; Stavros Gravas; Marco Carini; Sergio Serni
Journal:  Int J Endocrinol       Date:  2014-03-17       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.